Interleukin 1 Receptor Type 1 - Pipeline Review, H2 2019
Interleukin 1 Receptor Type 1 - Pipeline Review, H2 2019
SUMMARY
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Interleukin 1 receptor, type I (IL1R1) or CD121a is an interleukin receptor encoded by IL1R1 gene. It plays an important role in many cytokine-induced immune and inflammatory responses. It mediates activation of NF-kappa-B, MAPK and other pathways.
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Central Nervous System, Gastrointestinal, Respiratory, Cardiovascular, Dermatology, Ear Nose Throat Disorders, Genetic Disorders and Musculoskeletal Disorders which include indications Inflammation, Rheumatoid Arthritis, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Asthma, Atopic Dermatitis (Atopic Eczema), Autoimmune Inner Ear Disease (AIED), Bronchiolitis Obliterans, Cancer Anorexia-Cachexia Syndrome, Crohn's Disease (Regional Enteritis), Gouty Arthritis (Gout), Inflammatory Bowel Disease, Intracerebral Hemorrhage, Limited/Distal Colitis, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ), Myelodysplastic Syndrome, Myocarditis, Osteoarthritis Pain, Pain, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Renal Cell Carcinoma, Solid Tumor, Traumatic Brain Injury and Triple-Negative Breast Cancer (TNBC).
The latest report Interleukin 1 Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Interleukin 1 receptor, type I (IL1R1) or CD121a is an interleukin receptor encoded by IL1R1 gene. It plays an important role in many cytokine-induced immune and inflammatory responses. It mediates activation of NF-kappa-B, MAPK and other pathways.
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Central Nervous System, Gastrointestinal, Respiratory, Cardiovascular, Dermatology, Ear Nose Throat Disorders, Genetic Disorders and Musculoskeletal Disorders which include indications Inflammation, Rheumatoid Arthritis, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Asthma, Atopic Dermatitis (Atopic Eczema), Autoimmune Inner Ear Disease (AIED), Bronchiolitis Obliterans, Cancer Anorexia-Cachexia Syndrome, Crohn's Disease (Regional Enteritis), Gouty Arthritis (Gout), Inflammatory Bowel Disease, Intracerebral Hemorrhage, Limited/Distal Colitis, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ), Myelodysplastic Syndrome, Myocarditis, Osteoarthritis Pain, Pain, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Renal Cell Carcinoma, Solid Tumor, Traumatic Brain Injury and Triple-Negative Breast Cancer (TNBC).
The latest report Interleukin 1 Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)
- The report reviews Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Overview
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Companies Involved in Therapeutics Development
Immune System Key Ltd
Onspira Therapeutics Inc
Paradigm Biopharmaceuticals Ltd
Paras Biopharmaceuticals Finland Oy
ProteoThera Inc
Ribomic Inc
Swedish Orphan Biovitrum AB
XL-protein GmbH
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Drug Profiles
anakinra - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anakinra biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize IL-1R1 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-1510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBIL-1RA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nerofe - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Dormant Products
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Discontinued Products
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Product Development Milestones
Featured News & Press Releases
Oct 03, 2018: Results from the anaGO study - a phase 2 study with anakinra in patients with acute gout
Sep 21, 2018: Phase2a Nerofe study has begun in Rabin and Kaplan medical centers
Sep 20, 2018: New way to target advanced breast cancers
Apr 11, 2018: Kineret (anakinra) approved in the EU for the treatment of Still’s disease
Mar 26, 2018: Drug reduces inflammation in stroke patients
Feb 23, 2018: Kineret (anakinra) receives a positive opinion from CHMP for the treatment of Still’s disease
Nov 21, 2017: Successful Completion of Phase I Nerofe Trial on Solid Tumor
Nov 16, 2017: First patient randomised in a phase 3 study evaluating safety and efficacy of anakinra in the treatment of Still’s disease
May 30, 2017: Kineret approved in Canada for the treatment of Neonatal-Onset Multisystem Inflammatory Disease
Jan 11, 2017: First patient randomised in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout
Jun 06, 2016: Pfizer CentreOne to manufacture Sobi's Kineret drug substance
Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)
Feb 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)
Nov 01, 2015: Immune System Key: Nerofe's Triple Action
Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Overview
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Companies Involved in Therapeutics Development
Immune System Key Ltd
Onspira Therapeutics Inc
Paradigm Biopharmaceuticals Ltd
Paras Biopharmaceuticals Finland Oy
ProteoThera Inc
Ribomic Inc
Swedish Orphan Biovitrum AB
XL-protein GmbH
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Drug Profiles
anakinra - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anakinra biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize IL-1R1 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-1510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBIL-1RA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nerofe - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Dormant Products
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Discontinued Products
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Product Development Milestones
Featured News & Press Releases
Oct 03, 2018: Results from the anaGO study - a phase 2 study with anakinra in patients with acute gout
Sep 21, 2018: Phase2a Nerofe study has begun in Rabin and Kaplan medical centers
Sep 20, 2018: New way to target advanced breast cancers
Apr 11, 2018: Kineret (anakinra) approved in the EU for the treatment of Still’s disease
Mar 26, 2018: Drug reduces inflammation in stroke patients
Feb 23, 2018: Kineret (anakinra) receives a positive opinion from CHMP for the treatment of Still’s disease
Nov 21, 2017: Successful Completion of Phase I Nerofe Trial on Solid Tumor
Nov 16, 2017: First patient randomised in a phase 3 study evaluating safety and efficacy of anakinra in the treatment of Still’s disease
May 30, 2017: Kineret approved in Canada for the treatment of Neonatal-Onset Multisystem Inflammatory Disease
Jan 11, 2017: First patient randomised in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout
Jun 06, 2016: Pfizer CentreOne to manufacture Sobi's Kineret drug substance
Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)
Feb 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)
Nov 01, 2015: Immune System Key: Nerofe's Triple Action
Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Immune System Key Ltd, H2 2019
Pipeline by Onspira Therapeutics Inc, H2 2019
Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2019
Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2019
Pipeline by ProteoThera Inc, H2 2019
Pipeline by Ribomic Inc, H2 2019
Pipeline by Swedish Orphan Biovitrum AB, H2 2019
Pipeline by XL-protein GmbH, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Immune System Key Ltd, H2 2019
Pipeline by Onspira Therapeutics Inc, H2 2019
Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2019
Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2019
Pipeline by ProteoThera Inc, H2 2019
Pipeline by Ribomic Inc, H2 2019
Pipeline by Swedish Orphan Biovitrum AB, H2 2019
Pipeline by XL-protein GmbH, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Immune System Key Ltd
Onspira Therapeutics Inc
Paradigm Biopharmaceuticals Ltd
Paras Biopharmaceuticals Finland Oy
ProteoThera Inc
Ribomic Inc
Swedish Orphan Biovitrum AB
XL-protein GmbH
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Immune System Key Ltd
Onspira Therapeutics Inc
Paradigm Biopharmaceuticals Ltd
Paras Biopharmaceuticals Finland Oy
ProteoThera Inc
Ribomic Inc
Swedish Orphan Biovitrum AB
XL-protein GmbH
